نتائج البحث

FDA approves Zolgensma for infantile-onset SMA treatment: Zolgensma is the first gene therapy for the treatment of infantile-onset spinal muscular atrophy in children aged less than 2 years.

• Authors : Franki, Lucas

• Source: Neurology Reviews. Jul2019, Vol. 27 Issue 7, p12-12. 1/3p.

تفاصيل العنوان

$2.1 million gene therapy OK’d.

• Source: Science. 5/31/2019, Vol. 364 Issue 6443, p808-809. 2p.

تفاصيل العنوان

Gene Therapy for ALS—A Perspective.

• Authors : Cappella, Marisa¹ (AUTHOR); Ciotti, Chiara¹ (AUTHOR); Cohen-Tannoudji, Mathilde¹ (AUTHOR)

• Source: International Journal of Molecular Sciences. Sep2019, Vol. 20 Issue 18, p4388-4388. 1p. 2 Diagrams, 1 Chart.

تفاصيل العنوان

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives.

• Authors : Dangouloff, Tamara (AUTHOR); Servais, Laurent (AUTHOR)

• Source: Therapeutics & Clinical Risk Management. Oct2019, Vol. 15, p1153-1161. 9p.

تفاصيل العنوان

Cigna expands affordable access to gene therapies.

• Authors : Livingston, Shelby

• Source: Modern Healthcare. 9/9/2019, Vol. 49 Issue 35, p11-11. 1p.

تفاصيل العنوان